{'fraction_non_alphanumeric': 0.028523489932885907, 'fraction_numerical': 0.0, 'mean_word_length': 5.784090909090909, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia

Prophylaxis has become standard of care for persons with severe phenotype haemophilia (PWsH). However, ‘standard prophylaxis’ with either factor or non‐factor therapies (emicizumab) is prohibitively expensive for much of the world. We sought to evaluate whether haemophilia care can be provided at a lower cost yet achieve good results using Lower dose/Lower frequency prophylaxis (LDP) and with increasing use of antifibrinolytics (Tranexamic acid and Epsilon amino caproic acid).